One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” Q4 2025 ...
With only 11 episodes, Inuyashiki is an anime that premiered in 2017 and may have been quickly forgotten. Nevertheless, it's ...
In March, the companies announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). The study met its ...
Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...
Protagonist's pipeline leverages its proprietary Vectrix platform to target obesity, hematology, and inflammation. Find out ...
Protagonist Therapeutics has shared a closer look at midphase data on its Johnson & Johnson-partnered oral peptide psoriasis drug candidate. The efficacy fell short of the high bar set by injectable ...
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results